The *Acinetobacter baumannii* group: a systemic review

Hua-zhong Zhang, Jin-song Zhang, Li Qiao

Department of Emergency Medicine, First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China

**Corresponding Author:** Jin-song Zhang, Email: zhangjso@sina.com

**BACKGROUND:** The *Acinetobacter baumannii* group, including *Acinetobacter baumannii*, *Acinetobacter* genospecies 3 and 13TU, is phenotypically indistinguishable and uniformly identified as *Acinetobacter baumannii* by laboratories of clinical microbiology. This review aimed to demonstrate the differences among them.

**METHODS:** Literatures associated with the *Acinetobacter baumannii* group were identified and selected from PubMed databases and relevant journals.

**RESULTS:** *Acinetobacter* genospecies 3 and 13TU possess a certain proportion in clinical isolates. There were considerable differences in epidemiologic features, clinical manifestations, antimicrobial resistances and therapeutic options among the *Acinetobacter baumannii* group. Compared with *Acinetobacter* genospecies 3 and 13TU, *Acinetobacter baumannii* with a higher resistance to antimicrobial agents are easier to be treated inappropriately, and present a worse outcome in patients.

**CONCLUSION:** The *Acinetobacter baumannii* group comprises three distinct clinical entities, and their clinical value are not equal.

**KEY WORDS:** *Acinetobacter baumannii*; *Acinetobacter* genospecies 3; *Acinetobacter* genospecies 13TU; Difference

INTRODUCTION

The genus *Acinetobacter* currently consists of more than 40 genospecies,[1] of which *Acinetobacter baumannii* (*Acinetobacter* genospecies 2), *Acinetobacter* genospecies 3 and *Acinetobacter* genospecies 13TU are clinically most relevant genospecies.[2] They are phenotypically indistinguishable by use of routine laboratory technologies, the term "*Acinetobacter baumannii* group" has therefore been proposed to refer to these genospecies.[3]

In clinical microbiology laboratories, simple and reliable methods are barely available to complete the identification of the *Acinetobacter baumannii* group. Besides that DNA-DNA hybridization is regarded as the gold standard, other molecular typing methods also have been developed and validated. It is recommended that amplified 16S rRNA gene restriction analysis (ARDRA)[4] and amplified fragment length polymorphism (AFLP)[5] are the most widely accepted methods. However, they are too laborious and far from being suitable for day-to-day diagnostic microbiology. In fact, *Acinetobacter baumannii*, *Acinetobacter* genospecies 3 and *Acinetobacter* genospecies 13TU are uniformly identified as *Acinetobacter baumannii* by the most widely used identification systems.[6,7] In this review, we introduce the differences in epidemiologic features, clinical manifestations, antimicrobial resistances and therapeutic options among these three distinct clinical entities.

METHODS

Literatures associated with the *Acinetobacter baumannii* group were identified and selected from...
PubMed databases and relevant journals.

RESULTS

Differences in epidemiologic features

Few clinical centers have completed the identification of clinical isolates of the *Acinetobacter baumannii* group (Table 1). It is obvious that just as *Acinetobacter baumannii*, Acinetobacter genospecies 3 and 13TU are also important nosocomial pathogens and possess a certain proportion in clinical isolates. Isolates belonging to Acinetobacter genospecies 3 and 13TU were also involved in a number of outbreaks in ICUs. With the development of much more novel and accurate typing methodologies, an increase in infections caused by Acinetobacter genospecies 3 and 13TU might be observed in the future.

The genospecies of clinical isolates of the *Acinetobacter baumannii* group may vary considerably. In most regions, the *Acinetobacter baumannii* group was the most frequently isolated genospecies. But in Ireland and Germany, Acinetobacter genospecies 3 was found to be the most predominant genospecies. In addition, the proportions of *Acinetobacter baumannii* and Acinetobacter genospecies 3 were approximately equal in the Netherlands and Acinetobacter genospecies 13TU was the most prevalent genospecies in Norwegian blood cultures. It is a pity that by far there is no such report about the genospecies identification of the *Acinetobacter baumannii* group in the mainland of China, further studies are needed.

Differences in clinical manifestations

Ni et al found that *Acinetobacter baumannii* preferably colonized or infected the respiratory tract, and such infections tend to occur in debilitated patients especially in the ICU. In comparison, Acinetobacter genospecies 3 was more frequently involved in skin and soft tissue infections, such as surgical wound infection, and usually occurred in conventional wards, not in ICUs. Another study comparing the bacteremic nosocomial pneumonia caused by *Acinetobacter baumannii* and Acinetobacter genospecies 13TU found that patients with *Acinetobacter baumannii* pneumonia were more likely to have abnormal hematological findings, lobar pneumonia and significantly higher APACHE II scores than those with Acinetobacter genospecies 13TU pneumonia. It seemed that different genospecies would lead to different clinical manifestations among the *Acinetobacter baumannii* group.

Studies comparing the different clinical manifestations of the *Acinetobacter baumannii* group infections concentrated on the bloodstream infections. These studies confirmed that patients with *Acinetobacter baumannii* bacteremia were associated with a higher 14-day or 30-day mortality rate and an in-hospital mortality rate than those patients with bacteremia because of Acinetobacter genospecies 3 or 13TU. Patients with Acinetobacter genospecies 3 bacteremia and those with Acinetobacter genospecies 13TU had similar clinical features and outcomes. Multivariate analysis revealed that bacteremia caused by *Acinetobacter baumannii* was one of the independent factors associated with the all-cause mortality.

Patients with *Acinetobacter baumannii* bacteremia were more likely to have pneumonia, whereas those with bacteremia due to genospecies 13TU were more likely to have primary bacteremia. The Charlson Comorbidity Index was also significantly different in bloodstream infections of the *Acinetobacter baumannii* group. Patients with Acinetobacter genospecies 3 and 13TU bacteremia had obviously higher Charlson scores than patients with *Acinetobacter baumannii* bacteremia. They were implicated in more concurrent diseases, especially malignancy, and more metastatic malignancies were seen in patients with Acinetobacter genospecies 3 bacteremia. This may indicate a predilection of Acinetobacter genospecies 3 and 13TU in patients with malignancy. However, respiratory diseases such as COPD, pneumonia and mechanical ventilation were more prevalent in patients with *Acinetobacter baumannii* bacteremia. Multivariate analysis also found that total parenteral nutrition (TPN) was used more frequently and a longer timeframe in the treatment of TPN before the onset of bacteremia in patients with *Acinetobacter baumannii* bacteremia, who had received TPN for about 15 days before the onset of bacteremia. In addition, the duration from admission to the onset of bacteremia was a mean of 10 days longer in patients with

### Table 1. The distribution of the *Acinetobacter baumannii* group in clinical isolates

| Region      | A. baumannii group (%) | A. baumannii (%) | Genospecies 3 (%) | Genospecies 13TU (%) |
|-------------|------------------------|-----------------|------------------|---------------------|
| Ireland     | 72 (34.7)              | 25 (62.5)       | 45                | 2 (2.8)             |
| Singapore   | 193 (78.7)             | 18 (9.3)        | 15 (6.3)          | 98 (40.8)           |
| Korea       | 240 (52.9)             | 35 (85.7)       | 13 (2.8)          | 61 (22.5)           |
| USA         | 271 (69.0)             | 23 (8.5)        | 61 (22.5)         | 61 (22.5)           |
| Taiwan      | 1039 (42.3)            | 133 (12.8)      | 467 (44.9)        | 467 (44.9)          |
| Germany     | 1741 (19.2)            | 1053 (60.5)     | 353 (20.3)        | 353 (20.3)          |
**Acinetobacter baumannii** than in those with bacteremia because of Acinetobacter genospecies 3 and 13TU.[14,23] It is clear that different genospecies of the *Acinetobacter baumannii* group are not equal clinically. From a clinical and infection control point of view, identifying the *Acinetobacter baumannii* group to species level is necessary, and it indicates clinical significance.

**Differences in antimicrobial resistances: mechanisms and sensitivities**

The genus Acinetobacter has a propensity of rapidly acquiring resistance genes due to selective antimicrobial pressure and there are intrinsic resistance mechanisms typical to this genus, both of which lead to the high rates of resistance to multiple antimicrobial agents.[1] The mechanisms of antimicrobial resistance for genus Acinetobacter are shown in Table 2.

Studies also found that the antimicrobial resistance mechanisms were distinct for the *Acinetobacter baumannii* group. As for resistance to carbapenems, the blaIMP and blaVIM genes belonging to class B metallo-β-lactamase genes were more commonly found in Acinetobacter genospecies 3 and 13TU, whereas the class D carbapenemase genes were observed more often in *Acinetobacter baumannii*,[26,27] to which the blaOXA-51 gene was intrinsic.[28] For genes encoding aminoglycoside-modifying enzymes, *Acinetobacter baumannii* carried armA and aph(3')-Ia, whereas Acinetobacter genospecies 13TU possessed aph (3')-VI.[29] Moreover, *Acinetobacter baumannii* resistant to fluoroquinolones all contained a Ser83Leu substitution in the gyrA gene, but most of Acinetobacter genospecies 3 and 13TU were fluoroquinolones susceptible and contained a wild-type Ser83 in gyrA.[30,31] Furthermore, the presence of RND-type efflux systems was likely species-specific. Because AdeABC and AdeIJK efflux transporters were highly specific to *Acinetobacter baumannii*, AdeDE and AdeXYZ were predominant in Acinetobacter genospecies 3.[32,33] In addition, a study[34] investigated the different capacities of the *Acinetobacter baumannii* group to form biofilm at the air-liquid interface, which was almost 4 times higher for *Acinetobacter baumannii* and Acinetobacter genospecies 13TU than Acinetobacter genospecies 3.

The differences in antimicrobial resistance mechanisms as mentioned above were associated with various antimicrobial resistances among *Acinetobacter baumannii*, Acinetobacter genospecies 3 and 13TU. Although a considerable increase of resistance to almost all antimicrobial agents was noted in the *Acinetobacter baumannii* group globally,[35,36] *Acinetobacter* genomoespecies 3 and 13TU remained susceptible to the majority of antimicrobial agents.[30] It was generally observed that *Acinetobacter baumannii* isolates had significantly higher resistance rates than the other two genospecies in most antimicrobial tests which even including carbapenems and tigecycline.[24] At the same time, the proportions of multidrug resistant strains and carbapenems resistant strains were also significantly higher in *Acinetobacter baumannii* isolates than Acinetobacter genomoespecies 3 and 13TU.[12,24,36] However, it should be noted that Acinetobacter genomoespecies 3 and 13TU isolates were less susceptible to polymyxin E (colistin) than *Acinetobacter baumannii*. In addition, special

| Resistance mechanisms | Antimicrobial agents |
|-----------------------|---------------------|
| Produce antibiotics inactivated enzyme | β-lactams |
| β-lactamas | β-lactams |
| Class A: extended-spectrum β-lactamases (ESBLs): TEM, PER type | Aminoglycosides |
| Class B: the metallo-β-lactamases (MBLs): IMP, VIM, SIM type | Quinolones |
| Class C: AmpC cephalosporinases | Aminoglycosides |
| Class D: serine carbapenemases (OXA type) | β-lactams |
| Aminoglycoside-modifying enzymes (AMEs): APHS, AACs | Topoisomerase mutations in the genes gyrA and parC |
| Alter the action sites of antibiotics | Quinolones |
| Quinolones | Aminoglycosides |
| Aminoglycosides | β-lactams |
| β-lactams | Reduce the concentration of antibiotics in cells |
| Alteration in penicillin-binding proteins (PBPs) | Multidrug |
| Reduced permeability of the outer membrane | Tetracyclines |
| Efflux pumps | Multidrug |
| Plasmid-mediated transport protein: TetA, TetB, TetK | Multidrug |
| RND efflux systems: AdeABC, AdeDE, AdeXYZ, AdeIJK | Multidrug |
| Biofilm formation | Multidrug |
 attentions should be paid to that the colistin and tigecycline resistance rates for Acinetobacter genomospecies 13TU were up to about 20%.\cite{15,36} Therefore, it must be emphasized that the emergence of pan drug resistant Acinetobacter genomospecies 13TU might cause a great problem in the near future.

**Differences in therapeutic options**

As *Acinetobacter baumannii* display resistance to more classes of antimicrobial agents than Acinetobacter genospecies 3 and 13TU, patients with *Acinetobacter baumannii* infections tend to be less likely to receive appropriate empirical therapy.\cite{19,21,22,25} However, inappropriate antimicrobial therapy is just one of the factors independently associated with the mortality of patients with *Acinetobacter baumannii* infections.\cite{37}

The drug resistance to *Acinetobacter baumannii* leaves extremely limited therapy options for physicians to treat the patients with carbapenems resistant (CR), multiple drug resistant (MDR), extensive drug resistant (XDR) and even pan drug resistant (PDR) *Acinetobacter baumannii* infections. The use of tigecycline or polymyxin E (colistin) alone for severe CR, MDR and XDR *Acinetobacter baumannii* infections seems not to be an optimal choice.\cite{39} Case reports, case series and small comparative observational studies suggested that the combination antimicrobial therapies, such as the combination of colistin with rifampicin,\cite{39,40} tigecycline and colistin,\cite{40} were efficacious and demonstrated a lower-than-expected toxicity, but more clinical data obtained via controlled clinical trials were needed to confirm our preliminary conclusions. On the contrary, clinical isolates of Acinetobacter genomospecies 3 and 13TU were usually susceptible to a range of antimicrobial agents, and it was much easier to treat the patients infected with Acinetobacter genomospecies 3 or 13TU. The empirical antimicrobial agents including broad-spectrum-β-lactams and fluoroquinolones all displayed effective results.\cite{41}

The CHINET 2011 surveillance of bacterial resistance in China also displayed that cefoperazone/sulbactam had a relatively lower resistance rate for the genus Acinetobacter isolates, of which 88.6% belonged to *Acinetobacter baumannii*.\cite{42} When patients were considered to have been infected with *Acinetobacter baumannii*, without knowing the exact genospecies. Treatment was given with compound preparations containing sulbactam.\cite{43} A dose of sulbactam 4.0 g/d was efficacious and safe.\cite{38}

By now, studies on the differences in infections caused by *Acinetobacter baumannii* are rare, and more clinical data are needed to draw conclusions about the optimal therapies for each genospecies.

**DISCUSSION**

Although phenotypical differences could not be easily recognized in *Acinetobacter baumannii*, Acinetobacter genomospecies 3 and 13TU, they still had some differences in epidemiologic features, clinical manifestations, antimicrobial resistances and therapeutic options as demonstrated above. It could be concluded that *Acinetobacter baumannii* should be expressed as three clinical entities, and their clinic values were not equal. Compared with Acinetobacter genomospecies 3 and 13TU, the patients infected with *Acinetobacter baumannii* demonstrated greater antimicrobial resistances, and thus were more likely to receive inappropriate therapies. These findings emphasized the necessity of genospecies for better understanding the pathogenesis and epidemiology of infections caused by *Acinetobacter baumannii*. At the same time, the epidemiology and susceptibility of *Acinetobacter baumannii* may vary widely from hospital to hospital, surveillance of antimicrobial resistance and accurate identification of genospecies are important for physicians to develop appropriate therapies in treating patients with such infections.

**Funding:** The study was supported by a from grant Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

**Ethical approval:** Not needed.

**Conflicts of interest:** The authors declare that there is no conflict of interest.

**Contributors:** Zhang HZ designed the research, analyzed the data, and wrote the paper. All authors read and approved the final version.

**REFERENCES**

1. Kim DH, Park YK, Choi JY, Ko KS. Identification of genetic recombination between Acinetobacter species based on multilocus sequence analysis. Diagn Microbiol Infect Dis 2012; 73: 284–286.
2. Seifert H, Baginski R, Schulze A, Pulverer G. The distribution of Acinetobacter species in clinical culture materials. Zentralbl Bakteriol 1993; 279: 544–552.
3. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538–582.
4. Dijkshoorn L, Van Harsselaar B, Tjernberg I, Bouvet PJ,
Vaneechoutte M. Evaluation of amplified ribosomal DNA restriction analysis for identification of Acinetobacter genomic species. Syst Appl Microbiol 1998; 21: 33–39.

Janssen P, Maquelin K, Coopman R, Tjernberg I, Bouvet P, Kersters K, et al. Discrimination of Acinetobacter genomic species by AFLP fingerprinting. Int J Syst Bacteriol 1997; 47: 1179–1187.

Cai XF, Sun JM, Bao LS, Li WB. Risk factors and antibiotic resistance of pneumonia caused by multidrug resistant Acinetobacter baumannii in pediatric intensive care unit. World J Emerg Med 2012; 3: 202–207.

Horrevorts A, Bergman K, Kollée L, Breuker I, Tjernberg I, Dijkshoorn L. Clinical and epidemiological investigations of Acinetobacter genomospecies 3 in a neonatal intensive care unit. J Clin Microbiol 1995; 33: 1567–1572.

van Dessel H, Kamp-Hopmans TE, Fluit AC, Brisse S, de Smet AM, Dijkshoorn L, et al. Outbreak of a susceptible strain of Acinetobacter species 13 (sensu Tjernberg and Ursing) in an adult neurological intensive care unit. J Hosp Infect 2002; 51: 80–98.

Idzenega D, Schouten MA, van Zanten AR. Outbreak of Acinetobacter genomic species 3 in a Dutch intensive care unit. J Hosp Infect 2006; 63: 485–487.

McDonald A, Amyes SG, Paton R. The persistence and clonal spread of a single strain of Acinetobacter 13TU in a large Scottish teaching hospital. J Chemother 1999; 11: 338–344.

Boo TW, Walsh F, Crowley B. Molecular characterization of carbapenem-resistant Acinetobacter species in an Irish university hospital: predominance of Acinetobacter genomic species 3. J Med Microbiol 2009; 58: 209–216.

Koh TH, Tan TT, Khoo CT, Ng SY, Tan TY, Hsu LY, et al. Acinetobacter calcoaceticus-Acinetobacter baumannii complex species in clinical specimens in Singapore. Epidemiol Infect 2012; 140: 535–538.

Park YK, Jung SI, Park KH, Kim SH, Ko KS. Characteristics of carbapenem-resistant Acinetobacter spp. other than Acinetobacter baumannii in South Korea. Int J Antimicrob Agents 2012; 39: 81–85.

Wisplinghoff H, Paulus T, Lugenheim M, Stefanik D, Higgins PG, Edmond MB, et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect 2012; 64: 282–290.

Liang-Yu C, Kuo SC, Liu CY, Luo BS, Huang LJ, Lee YT, et al. Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, 1997–2007. J Microbiol Immunol Infect 2011; 44: 358–363.

Traub WH, Bauer D. Surveillance of nosocomial cross-infections due to three Acinetobacter genomospecies (Acinetobacter baumannii, genomospecies 3 and genomospecies 13) during a 10-Year Observation period: serotyping, macrorestriction analysis of Genomic DNA and antibiotic susceptibilities. Chemotherapy 2000; 46: 282–292.

van den Broek PJ, van der Reijden TJ, van Strijen E, Helmig-Schurter AV, Bernards AT, Dijkshoorn L. Endemic and epidemic acinetobacter species in a university hospital: an 8-year survey. J Clin Microbiol 2009; 47: 3593–3599.

Karah N, Haldorsen B, Hegstad K, Simonsen GS, Sundsfjord A, Samuelsen Ø. Species identification and molecular characterization of Acinetobacter spp. blood culture isolates from Norway. J Antimicrob Chemother 2011; 66: 738–744.

Ni HB, Zhang Z, Qin HD. Protective effect of glutamine in critical patients with acute liver injury. World J Emerg Med 2011; 2: 210–215.

Lee YT, Kuo SC, Yang SP, Lin YT, Chiang DH, Tseng FC, et al. Bacteremic nosocomial pneumonia caused by Acinetobacter baumannii and Acinetobacter nosocomialis: a single or two distinct clinical entities? Clin Microbiol Infect. 2012 Jul 12. [Epub ahead of print]

Lee NY, Chang TC, Wu CJ, Chang CM, Lee HC, Chen PL, et al. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia. J Infect 2010; 61: 219–227.

Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis 2011; 52: 352–360.

Chiang MC, Kuo SC, Chen SJ, Yang SP, Lee YT, Chen TL, et al. Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors. Infection 2012; 40: 19–26.

Lee YC, Huang YT, Tan CK, Kuo YW, Liao CH, Lee PI, et al. Acinetobacter baumannii and Acinetobacter genomospecies 13TU and 3 bacteremia: comparison of clinical features, prognostic factors and outcomes. J Antimicrob Chemother 2011; 66: 1839–1846.

Yin T, Chiang MC, Liaw JJ, Kuo SC, Chen TL, Katherine Wang KW. Clinical characteristics of Acinetobacter baumannii complex bacteremia in patients receiving total parenteral nutrition. J Chin Med Assoc 2012; 75: 102–108.

Cai XF, Sun JM, Bao LS, Li WB. Distribution and antibiotic resistance of pathogens isolated from ventilator-associated pneumonia patients in pediatric intensive care unit. World J Emerg Med 2011; 2: 117–121.

Lee JH, Choi CH, Kang HY, Lee JY, Kim J, Lee YC, et al. Differences in phenotypic and genotypic traits against antimicrobial agents between Acinetobacter baumannii and Acinetobacter genomic species 13TU. J Antimicrob Chemother 2007; 59: 633–639.

Asadollahi K, Alizadeh E, Akbari M, Taherikalani M, Niakan M, Maleki A, et al. The role of bla (OXA-like carbapenemase) and their insertion sequences (ISS) in the induction of resistance against carbapenem antibiotics among Acinetobacter baumannii isolates in Tehran hospitals. Roum Arch Microbiol Immunol 2011; 70: 153–158.

Cho YJ, Moon DC, Jin JS, Choi CH, Lee YC, Lee JC. Genetic basis of resistance to aminoglycosides in Acinetobacter spp. and spread of armA in Acinetobacter baumannii sequence group 1 in Korean hospitals. Diagn Microbiol Infect Dis 2009; 64: 185–190.

Liu YH, Kuo SC, Lee YT, Chang IC, Yang SP, Chen TL, et al. Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU. J Microbiol Immunol Infect 2012; 45: 108–112.

Sheng WH, Lin YC, Wang JT, Chen YC, Chang SC, Hsia KC,

www.wjem.org
et al. Identification of distinct ciprofloxacin susceptibility in Acinetobacter spp. by detection of the gyrA gene mutation using real-time PCR. Mol Cell Probes 2009; 23: 154–156.
32 Lin L, Ling BD, Li XZ. Distribution of the multidrug efflux pump genes, adeABC, adeDE and adeIJK, and class 1 integron genes in multiple-antimicrobial-resistant clinical isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex. Int J Antimicrob Agents 2009; 33: 27–32.
33 Chu YW, Chau SL, Houang ET. Presence of active efflux systems AdeABC, AdeDE and AdeXYZ in different Acinetobacter genomic DNA groups. J Med Microbiol 2006; 55: 477–478.
34 Martí S, Rodríguez-Baño J, Catel-Ferreira M, Jouenne T, Vila J, Seifert H, et al. Biofilm formation at the solid-liquid and air-liquid interfaces by Acinetobacter species. BMC Res Notes 2011; 4: 5.
35 Morfin-Otero R, Dowzicky MJ. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009. Clin Ther 2012; 34: 101–112.
36 Park YK, Jung SI, Park KH, Kim DH, Choi JY, Kim SH, et al. Changes in antimicrobial susceptibility and major clones of Acinetobacter calcoaceticus-baumannii complex isolates from a single hospital in Korea over 7 years. J Med Microbiol 2012; 61: 71–79.
37 Falagas ME, Kasiakou SK, Rafaellis PI, Zougaklas G, Morfos P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 2006; 57: 1251–1254.
38 Gilad J, Carmeli Y. Treatment options for multidrug-resistant Acinetobacter species. Drugs 2008; 68: 165–189.
39 Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2012 Sep 7. [Epub ahead of print]
40 Mutlu Yilmaz E, Sunbul M, Aksoy A, Yilmaz H, Gunsel AK, Guvenc T. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2012; 40: 332–336.
41 Espinal P, Roca I, Vila J. Clinical impact and molecular basis of antimicrobial resistance in non-baumannii Acinetobacter. Future Microbiol 2011; 6: 495–511.
42 Hu FP, Zhu DM, Wang F, Jiang XF, Yang Q, Xu YC, et al. CHINET 2011 surveillance of bacterial resistance in China. Chin J Infect Chemother 2012; 12: 321–329.
43 Gilad J, Carmeli Y. Treatment options for multidrug-resistant Acinetobacter species. Drugs 2008; 68: 165–189.

Received February 15, 2013
Accepted after revision June 21, 2013